Patents by Inventor Augustin Hittinger

Augustin Hittinger has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Dimers of artemisinin derivatives, preparation thereof and therapeutic use thereof
    Patent number: 8314142
    Abstract: The present invention relates to dimers of artemisinin derivatives, to processes for the preparation of such dimers, to methods of treatment comprising administration of such dimers, and to intermediates to such dimers.
    Type: Grant
    Filed: October 2, 2008
    Date of Patent: November 20, 2012
    Assignee: Sanofi
    Inventors: Alain Commerçon, Jidong Zhang, Augustin Hittinger
  • Pyrrolo(2,3-b) pyridine derivatives, the preparation and the pharmaceutical use thereof in the form of kinase inhibitors
    Patent number: 7968566
    Abstract: Novel compounds of formula (I): or pharmaceutically acceptable salts thereof, wherein R, R1, R2, R3, R4, R5, and R6 have the meanings given in the description, pharmaceutical compositions comprising said compounds and use thereof as protein kinase inhibitors.
    Type: Grant
    Filed: March 24, 2009
    Date of Patent: June 28, 2011
    Assignee: Aventis Pharma S.A.
    Inventors: Sylvie Wentzler, Youssef El-Ahmad, Bruno Filoche-Romme, Conception Nemecek, Corinne Venot, Augustin Hittinger
  • Cyclic urea compounds, preparation thereof and pharmaceutical use thereof as kinase inhibitors
    Patent number: 7825115
    Abstract: The disclosure relates to a cyclic urea compound of formula I: as defined herein, to the process for its preparation, pharmaceutical composition comprising it and its pharmaceutical use as an inhibitor on a protein kinase. Thus, the compound of formula I is useful for preventing or treating a physiological disorder capable of being modulated by inhibiting the activity of a protein kinase, such as a solid tumor.
    Type: Grant
    Filed: January 10, 2008
    Date of Patent: November 2, 2010
    Assignee: Aventis Pharma S.A.
    Inventors: Marcel Patek, Anil Nair, Augustin Hittinger, Conception Nemecek, Daniel Bond, Greg Harlow, Herve Bouchard, Jacques Mauger, Jean-Luc Malleron, Mark Palermo, Fahad Al-Obeidi, Thomas Faitg, Hartmut Strobel, Sven Ruf, Kurt Ritter, Youssef El-Ahmad, Dominique Lesuisse, Didier Bénard
  • Cyclic urea derivatives, preparation thereof and pharmaceutical use thereof as kinase inhibitors
    Patent number: 7759379
    Abstract: The invention relates to compounds of formula (I): in which R1, R2, L1, X, R3, A, R4, R4?, R4?, R4??, R5, Y and L2 are as herein defined, salts and prodrugs thereof, to their use as protein kinase inhibitors, and to methods of treating diseases comprising adminstration thereof.
    Type: Grant
    Filed: January 26, 2007
    Date of Patent: July 20, 2010
    Assignee: Aventis Pharma S.A.
    Inventors: Hartmut Strobel, Sven Ruf, Dominique Lesuisse, Conception Nemecek, Youssef El-Ahmad, Stefan Guessregen, Anne Lebrun, Kurt Ritter, Didier Benard, Augustin Hittinger, Hervé Bouchard
  • Pharmacological uses of azetidine derivatives
    Patent number: 7741316
    Abstract: A method of treating or preventing Alzheimer's disease, Parkinson's Disease and/or schizophrenia, this method comprising administering to a patient in need of such treatment a compound of formula: in which R, R3 and R4 are as defined in the specification.
    Type: Grant
    Filed: November 12, 2004
    Date of Patent: June 22, 2010
    Assignee: Aventis Pharma S.A.
    Inventors: Daniel Achard, Herve Bouchard, Jean Bouquerel, Bruno Filoche, Serge Grisoni, Augustin Hittinger, Michael R. Myers
  • NOVEL PYRROLO(2,3-b) PYRIDINE DERIVATIVES, THE PREPARATION AND THE PHARMACEUTICAL USE THEREOF IN THE FORM OF KINASE INHIBITORS
    Publication number: 20090233956
    Abstract: Novel compounds of formula (I): or pharmaceutically acceptable salts thereof, wherein R, R1, R2, R3, R4, R5, and R6 have the meanings given in the description, pharmaceutical compositions comprising said compounds and use thereof as protein kinase inhibitors.
    Type: Application
    Filed: March 24, 2009
    Publication date: September 17, 2009
    Applicant: Aventis Pharma S.A.
    Inventors: Sylvie Wentzler, Youssef El-Ahmad, Bruno Filoche-Romme, Conception Nemecek, Corinne Venot, Augustin Hittinger
  • Pyrrolo (2,3-b)pyridine derivatives, the preparation and the pharmaceutical use thereof in the form of kinase inhibitors
    Patent number: 7528147
    Abstract: Novel compounds of formula (I): or pharmaceutically acceptable salts thereof, wherein R, R1, R2, R3, R4, R5, and R6 have the meanings given in the description, pharmaceutical compositions comprising said compounds and use thereof as protein kinase inhibitors.
    Type: Grant
    Filed: September 29, 2006
    Date of Patent: May 5, 2009
    Assignee: Aventis Pharma S.A.
    Inventors: Sylvie Wentzler, Youssef El-Ahmad, Bruno Filoche-Rommé, Conception Nemecek, Corinne Venot, Augustin Hittinger
  • DIMERS OF ARTEMISININ DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF
    Publication number: 20090082426
    Abstract: The present invention relates to dimers of artemisinin derivatives, to processes for the preparation of such dimers, to methods of treatment comprising administration of such dimers, and to intermediates to such dimers.
    Type: Application
    Filed: October 2, 2008
    Publication date: March 26, 2009
    Applicant: SANOFI-AVENTIS
    Inventors: Alain COMMERCON, Jidong ZHANG, Augustin HITTINGER
  • Cyclic Urea Compounds, Preparation Thereof and Pharmaceutical Use Thereof as Kinase Inhibitors
    Publication number: 20080108654
    Abstract: The disclosure relates to a cyclic urea compound of formula I: as defined herein, to the process for its preparation, pharmaceutical composition comprising it and its pharmaceutical use as an inhibitor on a protein kinase. Thus, the compound of formula I is useful for preventing or treating a physiological disorder capable of being modulated by inhibiting the activity of a protein kinase, such as a solid tumor.
    Type: Application
    Filed: January 10, 2008
    Publication date: May 8, 2008
    Applicant: AVENTIS PHARMA S.A.
    Inventors: Marcel PATEK, Anil NAIR, Augustin HITTINGER, Conception NEMECEK, Daniel BOND, Greg HARLOW, Herve BOUCHARD, Jacques MAUGER, Jean-Luc MALLERON, Mark PALERMO, Fahad AL-OBEIDI, Thomas FAITG, Hartmut STROBEL, Sven RUF, Kurt RITTER, Youssef EL-AHMAD, Dominique LESUISSE
  • Cyclic urea derivatives, preparation thereof and pharmaceutical use thereof as kinase inhibitors
    Patent number: 7354933
    Abstract: The present invention relates to a cyclic urea compound of formula I: as defined herein. The invention is also directed to the process for its preparation, pharmaceutical composition comprising it and its pharmaceutical use, as an inhibitor on a protein kinase. Thus, it is useful for preventing or treating a physiological disorder capable of being modulated by inhibiting the activity of a protein kinase, such as a solid tumor.
    Type: Grant
    Filed: February 2, 2004
    Date of Patent: April 8, 2008
    Assignee: Aventis Pharma SA
    Inventors: Marcel Patek, Anil Nair, Augustin Hittinger, Conception Nemecek, Daniel Bond, Greg Harlow, Herve Bouchard, Jacques Mauger, Jean-Luc Malleron, Mark Palermo, Fahad Al-Obeidi, Thomas Faitg, Hartmut Strobel, Sven Ruf, Kurt Ritter, Youssef El-Ahmad, Dominique Lesuisse, Didier Bénard
  • Cyclic Urea Derivatives, Preparation Thereof And Pharmaceutical Use Thereof As Kinase Inhibitors
    Publication number: 20080004300
    Abstract: The invention relates to compounds of formula (I): in which R1, R2, L1, X, R3, A, R4, R4?, R4?, R4??, R5, Y and L2 are as herein defined, salts and prodrugs thereof, to their use as protein kinase inhibitors, and to methods of treating diseases comprising adminstration thereof.
    Type: Application
    Filed: January 26, 2007
    Publication date: January 3, 2008
    Applicant: Aventis Pharma S.A.
    Inventors: Hartmut Strobel, Sven Ruf, Dominique Lesuisse, Conception Nemecek, Youssef El-Ahmad, Stefan Guessregen, Anne Lebrun, Kurt Ritter, Didier Benard, Augustin Hittinger, Herve Bouchard
  • Chemical derivatives as antitelomerase agents which bind specifically to the G-quadruplex DNA structures and their application as a specific anticancer agent
    Publication number: 20070232572
    Abstract: The present invention relates to cancer therapy and to novel anticancer agents having a mechanism of action which is quite specific. It also relates to novel chemical compounds and their therapeutic application in humans.
    Type: Application
    Filed: February 6, 2004
    Publication date: October 4, 2007
    Applicants: Aventis Pharma S.A., Centre National De La Recherche Scientifique, Museum National D'Histoire Naturelle, Institut Curie, Commissariat A L'Energie Atomique, Universite De Reims Champagne-Ardenne
    Inventors: Augustin Hittinger, Thomas Caulfield, Patrick Mailliet, Herve Bouchard, Eliane Mandine, Jean-Louis Mergny, Lionel Guittat, Jean-Francois Riou, Dennis Gomez, Chafke Belmokhtar
  • Novel pyrrolo (2,3-b)pyridine derivatives, the preparation and the pharmaceutical use thereof in the form of kinase inhibitors
    Publication number: 20070093480
    Abstract: Novel compounds of formula (I): or pharmaceutically acceptable salts thereof, wherein R, R1, R2, R3, R4, R5, and R6 have the meanings given in the description, pharmaceutical compositions comprising said compounds and use thereof as protein kinase inhibitors.
    Type: Application
    Filed: September 29, 2006
    Publication date: April 26, 2007
    Applicant: Aventis Pharma S.A.
    Inventors: Sylvie Wentzler, Youssef El-Ahmad, Bruno Filoche-Romme, Conception Nemecek, Corinne Venot, Augustin Hittinger
  • AZETIDINE DERIVATIVES, THEIR PREPARATION AND MEDICAMENTS CONTAINING THEM
    Publication number: 20060270649
    Abstract: Disclosed are azetidine derivatives of formula: their optical isomers, their salts, their preparation and medicaments containing them.
    Type: Application
    Filed: May 25, 2006
    Publication date: November 30, 2006
    Applicant: Aventis Pharma S.A.
    Inventors: Daniel Achard, Herve Bouchard, Jean Bouquerel, Marc Capet, Serg Grisoni, Jean-Luc Malleron, Serge Mignani, Augustin Hittinger
  • Pharmaceutical compositions containing 3-aminoazetidine derivatives, novel derivatives and their preparation
    Patent number: 7132414
    Abstract: The present invention relates to pharmaceutical compositions containing, as active ingredient, a compound of formula: in which R1 represents a radical —NHCOR4 or —N(R5)—Y—R6, Y is CO or SO2, R4 represents a radical -alk-SO2—R11, -alk-SO2—CH?CH—R11 or Het substituted with —SO2—R11 or a phenyl radical substituted with —SO2—R11 or -alk-SO2—R11, R5 represents a hydrogen atom or an alkyl radical, R6 represents a phenylalkyl, Het or Ar radical, to the novel derivatives of formula (I) and to their preparation, as well s to their use in treating various disorders of the nervous system.
    Type: Grant
    Filed: February 4, 2004
    Date of Patent: November 7, 2006
    Assignee: Aventis Pharma S.A.
    Inventors: Daniel Achard, Herve Bouchard, Jean Bouquerel, Bruno Filoche, Serge Grisoni, Augustin Hittinger, Michael R. Myers
  • Chemical derivatives and their application as antitelomerase agent
    Publication number: 20060199840
    Abstract: The present invention relates to cancer therapy and to novel anticancer agents having a mechanism of action which is quite specific. It also relates to novel chemical compounds as well as their therapeutic application in humans.
    Type: Application
    Filed: September 8, 2005
    Publication date: September 7, 2006
    Applicant: Aventis Pharma S.A.
    Inventors: Herve Bouchard, Augustin Hittinger
  • Chemical derivatives and their application as antitelomerase agent
    Patent number: 6995175
    Abstract: The present invention relates to cancer therapy and to novel anticancer agents having a mechanism of action which is quite specific. It also relates to novel chemical compounds as well as their therapeutic application in humans.
    Type: Grant
    Filed: November 25, 2003
    Date of Patent: February 7, 2006
    Assignee: Aventis Pharma S.A.
    Inventors: Hervé Bouchard, Augustin Hittinger
  • Pharmacological uses of azetidine derivatives
    Publication number: 20050130953
    Abstract: A method of treating or preventing Alzheimer's disease, Parkinson's Disease and/or schizophrenia, this method comprising administering to a patient in need of such treatment a compound of formula: in which R, R3 and R4 are as defined in the specification.
    Type: Application
    Filed: November 12, 2004
    Publication date: June 16, 2005
    Applicant: Aventis Pharma S.A.
    Inventors: Daniel Achard, Herve Bouchard, Jean Bouquerel, Bruno Filoche, Serge Grisoni, Augustin Hittinger, Michael Myers
  • Pharmacological uses of azetidine derivatives
    Patent number: 6872717
    Abstract: A method of treating or preventing obesity, this method comprising administering to a patient in need of such treatment an effective amount of a compound of formula in which R, R3 and R4 are as defined in the specification.
    Type: Grant
    Filed: September 12, 2002
    Date of Patent: March 29, 2005
    Assignee: Aventis Pharma S.A.
    Inventors: Daniel Achard, Hervé Bouchard, Jean Bouquerel, Bruno Filoche, Serge Grisoni, Augustin Hittinger, Michael R. Myers
  • Acetindine derivatives, their preparation and medicaments containing them
    Patent number: 6858603
    Abstract: Disclosed are azetidine derivatives of formula: their optical isomers, their salts, their preparation and medicaments containing them.
    Type: Grant
    Filed: December 16, 2002
    Date of Patent: February 22, 2005
    Assignee: Aventis Pharma S.A.
    Inventors: Daniel Achard, Hervé Bouchard, Jean Bouquerel, Marc Capet, Serg Grisoni, Jean-Luc Malleron, Serge Mignani, Augustin Hittinger